Attenuation of mecamylamine-precipitated nicotine-withdrawal aversion by the 5-HT3 receptor antagonist ondansetron.
The effect of ondansetron (0.01-0.1 mg/kg, s.c.), a selective 5-HT3 receptor antagonist, on mecamylamine-precipitated nicotine-withdrawal aversion was examined in the conditioned place preference paradigm. Male Sprague-Dawley rats were chronically treated subcutaneously with 9 mg/kg/day (-)-nicotine tartrate using an osmotic minipump. After nicotine treatment for 7 days, mecamylamine (1 mg/kg, s.c.), a nicotinic receptor antagonist, produced place aversion in nicotine-dependent rats. This aversive effect was dose-dependently antagonized by pretreatment with ondansetron 30 min prior to the conditioning. These results suggest that ondansetron may attenuate the place aversion associated with nicotine withdrawal, and may be useful for the treatment of nicotine dependence.
Suzuki
T
T
Department of Pharmacology, School of Pharmacy, Hoshi University, Tokyo, Japan.
Ise
Y
Y
Mori
T
T
Misawa
M
M
D000818:Animals; D003213:Conditioning, Psychological / Q000187:drug effects; D008297:Male; D008464:Mecamylamine / Q000494:pharmacology*; D009538:Nicotine / Q000009:adverse effects*; D018733:Nicotinic Antagonists / Q000494:pharmacology*; D017294:Ondansetron / Q000494:pharmacology*; D051381:Rats; D017207:Rats, Sprague-Dawley; D012702:Serotonin Antagonists / Q000494:pharmacology*; D013375:Substance Withdrawal Syndrome
D018733:Nicotinic Antagonists; D012702:Serotonin Antagonists; D017294:Ondansetron; D008464:Mecamylamine; D009538:Nicotine